Confirmed COVID-19 cases have surpassed 57.5 million globally with over 1.3 million fatalities on Saturday, according to Johns Hopkins University data.

The worldwide Covid-19 caseload crossed 55 million on Friday, taking the tally to 56,898,415, according to Johns Hopkins University data.   Besides, the death toll from Covid-19 shot up to 1,360,381.   The United States remains the worst-hit country with 11,715,316 confirmed cases so far, including 252,535 fatalities.   But with coronavirus cases surging and people preparing to gather for Thanksgiving, the situation is likely to worsen. The nation’s testing system remains unable to keep pace with the virus, reports AP.   The delays are happening as the country braces for winter weather, flu season and holiday travel, all of which are expected to amplify the US outbreak.   Meanwhile, since Feb 2 when Brazil reported its first case, the caseload has swelled to 5,945,849 with 167,455 deaths.   Mexico became the fourth country to register over 100,000 COVID-19 deaths.   José Luis Alomía Zegarra, Mexico’s director of epidemiology, announced late Thursday that Mexico had 100,104 confirmed COVID-19 deaths, behind only the United States, Brazil and India.   On Friday, India’s coronavirus cases since the pandemic began crossed 9 million.   The country’s new daily cases have seen a steady decline for weeks now and the total number of cases represents 0.6 percent of India’s 1.3 billion population.   The Indian Health Ministry reported 45,882 new infections and 584 fatalities in the past 24 hours on Friday. The death toll is more than 132,000.   Vaccine hope   A second experimental COVID-19 vaccine from American company Moderna Inc yielded extraordinarily strong early results last week.   Moderna said its vaccine appears to be 94.5 percent effective, according to preliminary data from an ongoing study. A week before that another US company Pfizer Inc announced its own vaccine looked 90 percent effective.   The University of Oxford expects to release data on the efficacy of its own candidate in the coming weeks, with the latest trial results published in The Lancet suggesting it produces a strong immune response in older adults.   Developed jointly with global pharma giant AstraZeneca, who have enlisted manufacturing partners in different parts of the world, the ChAdOx1 nCov-2019 vaccine is the one most likely to play a large role in any large or medium-scale vaccination effort in Bangladesh.